HRP20171699T1 - Formulacija anestetika - Google Patents

Formulacija anestetika Download PDF

Info

Publication number
HRP20171699T1
HRP20171699T1 HRP20171699TT HRP20171699T HRP20171699T1 HR P20171699 T1 HRP20171699 T1 HR P20171699T1 HR P20171699T T HRP20171699T T HR P20171699TT HR P20171699 T HRP20171699 T HR P20171699T HR P20171699 T1 HRP20171699 T1 HR P20171699T1
Authority
HR
Croatia
Prior art keywords
preparation according
cyclodextrin
anesthetic
neuroactive steroid
preparation
Prior art date
Application number
HRP20171699TT
Other languages
English (en)
Croatian (hr)
Inventor
Juliet Marguerite Goodchild
Colin Stanley Goodchild
Benjamin James Boyd
Original Assignee
Drawbridge Pharmaceuticals Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drawbridge Pharmaceuticals Pty Ltd. filed Critical Drawbridge Pharmaceuticals Pty Ltd.
Publication of HRP20171699T1 publication Critical patent/HRP20171699T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171699TT 2010-01-21 2011-01-19 Formulacija anestetika HRP20171699T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US38531810P 2010-09-22 2010-09-22
EP11734245.1A EP2525798B1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (1)

Publication Number Publication Date
HRP20171699T1 true HRP20171699T1 (hr) 2018-01-26

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171699TT HRP20171699T1 (hr) 2010-01-21 2011-01-19 Formulacija anestetika

Country Status (27)

Country Link
US (2) US8697678B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2525798B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5930311B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101747476B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102802635B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2011207103B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012017800B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2786762C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2012002032A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1119947T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2525798T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2646829T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB2491491B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20171699T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE035441T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2525798T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2525798T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ601255A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2525798T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2525798T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS56576B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2574022C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG181997A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2525798T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT201700518T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011088503A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201205370B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201506273PA (en) * 2011-11-29 2015-09-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
PL2806877T3 (pl) * 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
IL252848B2 (en) * 2015-02-06 2024-07-01 Marinus Pharmaceuticals Inc Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
JP2018530585A (ja) 2015-10-16 2018-10-18 マリナス ファーマシューティカルズ インコーポレイテッド ナノ粒子を含む注射可能な神経ステロイド製剤
TW202400182A (zh) 2016-03-08 2024-01-01 美商賽吉醫療公司 神經活性類固醇,其組合物及用途
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN111971238B (zh) 2018-04-16 2022-02-18 川崎重工业株式会社 带式输送机
US11472833B2 (en) 2018-07-03 2022-10-18 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022514991A (ja) * 2018-12-10 2022-02-16 ハロー・サイエンス・エル・エル・シー 安定な麻酔薬製剤および関連する剤形
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
CN119950517A (zh) 2019-12-06 2025-05-09 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE100712T1 (de) * 1989-05-24 1994-02-15 Innovet Inc Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
CA2631233C (en) * 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof

Also Published As

Publication number Publication date
RU2012134321A (ru) 2014-02-27
CA2786762C (en) 2017-12-05
HUE035441T2 (en) 2018-05-02
US20120316146A1 (en) 2012-12-13
CY1119947T1 (el) 2018-12-12
NO2525798T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-06
GB2484244B (en) 2012-10-31
GB201201842D0 (en) 2012-03-21
EP2525798B1 (en) 2017-08-09
SI2525798T1 (en) 2018-01-31
SMT201700518T1 (it) 2018-01-11
US20140066417A1 (en) 2014-03-06
EP2525798A1 (en) 2012-11-28
GB2491491B (en) 2014-07-30
RS56576B1 (sr) 2018-02-28
HK1169031A1 (en) 2013-01-18
WO2011088503A1 (en) 2011-07-28
US8697678B2 (en) 2014-04-15
LT2525798T (lt) 2018-01-10
ES2646829T3 (es) 2017-12-18
GB2491491A (en) 2012-12-05
AU2011207103A1 (en) 2012-07-26
RU2574022C2 (ru) 2016-01-27
KR101747476B1 (ko) 2017-06-14
JP5930311B2 (ja) 2016-06-08
BR112012017800A8 (pt) 2018-08-14
BR112012017800A2 (pt) 2018-07-10
NZ601255A (en) 2013-09-27
JP2013517299A (ja) 2013-05-16
EP2525798A4 (en) 2014-02-19
CN102802635B (zh) 2014-07-30
DK2525798T3 (da) 2017-11-20
CL2012002032A1 (es) 2012-12-21
BR112012017800B1 (pt) 2020-12-08
PT2525798T (pt) 2017-11-15
US8975245B2 (en) 2015-03-10
CN102802635A (zh) 2012-11-28
AU2011207103B2 (en) 2013-03-21
GB201210657D0 (en) 2012-08-01
GB2484244A (en) 2012-04-04
PL2525798T3 (pl) 2018-05-30
SG181997A1 (en) 2012-08-30
ZA201205370B (en) 2013-09-25
CA2786762A1 (en) 2011-07-28
KR20120136347A (ko) 2012-12-18

Similar Documents

Publication Publication Date Title
HRP20171699T1 (hr) Formulacija anestetika
HRP20192348T1 (hr) Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina
HRP20191216T1 (hr) Formulacije testosterona
JP2013517299A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HRP20210819T1 (hr) Fenfluramin za uporabu u liječenju dravet sindroma
HRP20161280T1 (hr) Farmaceutski pripravci
HRP20211686T1 (hr) Formulacije intravenozne otopine sa posakonazolom, stabilizirane supstituiranim beta-ciklodekstrinom
JP2014240439A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HRP20200255T1 (hr) Formulacija ac220 osušena raspršivačem
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
HRP20140051T1 (hr) Farmaceutski pripravci koji sadrže imidazokinolin(amine) i njihovi derivati prikladni za lokalno davanje
TN2012000574A1 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
HRP20150819T1 (hr) Derivati metastina i njihova uporaba
RS53876B1 (en) PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS
JO3354B1 (ar) صيغة تتألف من جسيمات افيرميكتين مغلفة بعامل واقي من الضوء
BRPI0922804B8 (pt) composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável
HRP20170021T1 (hr) Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
HRP20151214T4 (hr) Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti
JP2009544665A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA2692191C (en) Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
MX2011010547A (es) Composiciones farmaceuticas estables de diclofenaco.
EP2486914A3 (en) Stable, non-corrosive formulations for pressurized metered dose inhalers
HRP20141273T1 (hr) Halogenirani kompleks etera